Evidence map›Paper›PMID 42798447›Full record

ArticleFrontiers in sports and active living2026

Impact of a 2-year structured program on physical fitness and physical activity in T2D patients with rapid renal function decline-the ACTIDIANE RCT.

Laurent Bosquet, Martine Duclos, Gaël Ennequin, Elsa Heyman, Mélanie Marias, Laurent Mourot, Philippe Sosner, Oualid Ayad, Edith Bigot Corbel, Sophie Borot and 24 more

Abstract read
In one paragraph

Article in Frontiers in sports and active living, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Laurent BosquetLaboratoire MOVE (UR20296), Université de Poitiers, Poitiers, France.
Martine DuclosService de Médecine du Sport et des Explorations Fonctionnelles, Université Clermont Auvergne, CHU de Clermont-Ferrand, Clermont-Ferrand, France.
Gaël EnnequinLaboratoire AME2P, Université Clermont-Auvergne, Clermont Ferrand, France.
Elsa HeymanUniv. Lille, Univ. Artois, Univ. Littoral Côte d'Opale, ULR 7369 - URePSSS - Unité de Recherche Pluridisciplinaire Sport Santé Société, Lille, France.
Mélanie MariasLaboratoire MOVE (UR20296), Université de Poitiers, Poitiers, France.
Laurent MourotLaboratoire Synergies, Université de Franche Comté, Besançon, France.
Philippe SosnerLaboratoire MOVE (UR20296), Université de Poitiers, Poitiers, France.
Oualid AyadUniversité de Poitiers, CHU de Poitiers, Centre d'Investigation Clinique (CIC INSERM 1402), Poitiers, France.
Edith Bigot CorbelDépartement d'Endocrinologie (CIC INSERM 1413), Nantes Université, CHU de Nantes, Institut du Thorax, Nantes, France.
Sophie BorotService D'Endocrinologie-Diabétologie-Nutrition, Hôpital Minjoz, Université de Franche-Comté, CHU de Besançon, Besançon, France.
Claire CaretteDépartment de Nutrition (centre de l'obésité), Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris (INSERM CIC1418), Université Paris Cité, Paris, France.
Bertrand CariouDépartement d'Endocrinologie (CIC INSERM 1413), Nantes Université, CHU de Nantes, Institut du Thorax, Nantes, France.
Nicolas ChevalierService d'Endocrinologie, Diabétologie & Médecine de la Reproduction, Hôpital de l'Archet 2, Nice, France.
Cécile CianguraDépartement de Diabétologie, Hôpital de la Pitié-Salpêtrière, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Institut de Cardiometabolisme et Nutrition (ICAN), Paris, France.
Severine ClerjaudUniversité de Poitiers, CHU de Poitiers, Centre d'Investigation Clinique (CIC INSERM 1402), Poitiers, France.
Pierre-Henri DucluzeauDépartment d'Endocrinologie-Diabetologie-Nutrition, CHU of Tours, Tours, France.
Lisa DurocherUniversité de Poitiers, CHU de Poitiers, Centre d'Investigation Clinique (CIC INSERM 1402), Poitiers, France.
Jean François GautierUniversité Paris Cité, Hôpital Lariboisière, Centre Universitaire du Diabète et de ses Complications, Paris, France.
Pierre GourdyUniversité de Toulouse, CHU de Toulouse (UMR1297/I2MC), Toulouse, France.
Amine KasmiUniversité de Poitiers, CHU de Poitiers, Centre d'Investigation Clinique (CIC INSERM 1402), Poitiers, France.
Laurence KesslerDépartement de Diabetologie, Inserm UMR 1260, Université de Strasbourg, CHU de Strasbourg, Strasbourg, France.
Arnaud MonierDiabétologie Endocrinologie, Centre Hospitalier Louis Pasteur, Le Coudray, France.
Pierre MorcelDépartement d'Endocrinologie (CIC INSERM 1413), Nantes Université, CHU de Nantes, Institut du Thorax, Nantes, France.
Myriam MoretService D'endocrinologie, de Diabétologie et des Maladies Métaboliques, Hospices Civils de Lyon, Hôpital Louis Pradel, Bron, France.
Philippe MoulinService D'endocrinologie, de Diabétologie et des Maladies Métaboliques, Hospices Civils de Lyon, Hôpital Louis Pradel, Bron, France.
Nicolas PaquotNutrition et Maladies Métaboliques, Université de Liège, CHU Liège, Unité de Diabétologie, Liège, Belgique.
Stéphanie RagotUniversité de Poitiers, CHU de Poitiers, Centre d'Investigation Clinique (CIC INSERM 1402), Poitiers, France.
Vincent RigalleauService Endocrinologie-Nutrition, CHU Bordeaux, Hospital Haut-Lévêque, Pessac, France.
Pierre-Jean SaulnierUniversité de Poitiers, CHU de Poitiers, Centre d'Investigation Clinique (CIC INSERM 1402), Poitiers, France.
André ScheenNutrition et Maladies Métaboliques, Université de Liège, CHU Liège, Unité de Diabétologie, Liège, Belgique.
Igor TauveronService Endocrinologie Diabétologie, Université Clermont Auvergne, CHU de Clermont-Ferrand, Clermont-Ferrand, France.
Anne VambergueDépartement Diabetes et Nutrition, Université de Lille, CHU Lille, Lille, France.
Tiphaine Vidal TrecanUniversité Paris Cité, Hôpital Lariboisière, Centre Universitaire du Diabète et de ses Complications, Paris, France.
Samy HadjadjDépartement d'Endocrinologie (CIC INSERM 1413), Nantes Université, CHU de Nantes, Institut du Thorax, Nantes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-term structured physical activity (PA) programs remain insufficiently evaluated in real-life settings for individuals living with type 2 diabetes (T2D). We assessed the effects of a 2-year high-intensity physical activity (HIPA) program on physical fitness and spontaneous PA. Methods: ACTIDIANE was a 21-center, open-label, randomized controlled trial comparing HIPA with standard PA recommendations (PAR) in 103 adults with T2D and rapid renal function decline. The HIPA intervention consisted of two supervised sessions per week delivered by certified adapted physical activity professionals over 24 months. Physical fitness and spontaneous PA were pre-specified secondary outcomes of the trial. Mixed models assessed group-by-time interactions over 24 months. Results: Baseline characteristics were similar between groups. Estimated Conclusions: In adults with T2D and rapid renal function decline, a 2-year structured HIPA program significantly improved estimated cardiorespiratory fitness, a clinically meaningful finding given the strong association between

Indexed as

adherencehigh-intensity physical activityrandomized controlled trialsedentaritytype 2 diabetes

Identifiers

PMID42798447
PMCPMC13612428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.